HEPA - Hepion Pharmaceuticals, Inc. Operating income before deduction of amortization

The absence of stable revenues precludes dividend payments, creating risks in the event of failed tests. Total EBITDA for the period serves as an indicator of confidence in the business's maturity, where represents the latest metric reading. Revenue growth is based on the commercialization of rencisiflovir against liver fibrosis. Meanwhile, the US localization of patents minimizes external geopolitical threats for Hepion Pharmaceuticals (HEPA).

For biopharmaceutical innovator Hepion Pharmaceuticals (HEPA), which specializes in the therapy of liver cirrhosis and fibrosis, operational efficiency depends directly on the ability to maintain daily liquidity during the R&D period. This indicator aggregates net cash flow from operating activities per day, allowing the tracking of the real speed of fund generation via EBITDA and the avoidance of investment blind spots between quarters.